Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

Clinical Science

Volumn 118, Issue 4, 2010, Pages 241-247

  Mokhtari, Dariush ^a   Welsh, Nils ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

cell; Abl; Diabetes; Imatinib; Platelet derived growth factor receptor (PDGFR); Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; DASATINIB; ERLOTINIB; FASUDIL; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB;

APOPTOSIS; CELL PROLIFERATION; CELL PROTECTION; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 70549110925     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090348     Document Type: Review

References (50)

1. Mathis, D., Vence, L. and Benoist, C. (2001) β-Cell death during progression to diabetes. Nature 414, 792-798
2. Cnop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S. and Eizirik, D. L. (2005) Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (Suppl. 2), S97-S107
3. Eizirik, D. L. and Mandrup-Poulsen, T. (2001) A choice of death: the signal-transduction of immune-mediated β-cell apoptosis. Diabetologia 44, 2115-2133
4. Skyler, J. S. (2008) Update on worldwide efforts to prevent type 1 diabetes. Ann. N.Y. Acad. Sci. 1150, 190-196
5. Maekawa, T., Ashihara, E. and Kimura, S. (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int. J. Clin. Oncol. 12, 327-340
6. Hantschel, O., Rix, U. and Superti-Furga, G. (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49, 615-619
7. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652
8. Little, P. J., Cohen, N. and Morahan, G. (2009) Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. ScientificWorldJournal 9, 224-228
9. Breccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F. and Alimena, G. (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J. Clin. Oncol. 22, 4653-4655
10. Veneri, D., Franchini, M. and Bonora, E. (2005) Imatinib and regression of type 2 diabetes. N. Engl. J. Med. 352, 1049-1050
11. Breccia, M., Muscaritoli, M. and Alimena, G. (2005) Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. Haematologica 90 (Suppl.), ECR21
12. Billemont, B., Medioni, J., Taillade, L., Helley, D., Meric, J. B., Rixe, O. and Oudard, S. (2008) Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99, 1380-1382
13. Breccia, M., Muscaritoli, M., Cannella, L., Stefanizzi, C., Frustaci, A. and Alimena, G. (2008) Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk. Res. 32, 1626-1628
14. Templeton, A., Brandle, M., Cerny, T. and Gillessen, S. (2008) Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann. Oncol. 19, 824-825
15. Costa, D. B. and Huberman, M. S. (2006) Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care 29, 1711
16. Tsapas, A., Vlachaki, E., Sarigianni, M., Klonizakis, F. and Paletas, K. (2008) Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leuk. Res. 32, 674-675
17. Kikuchi, Y., Yamada, M., Imakiire, T., Kushiyama, T., Higashi, K., Hyodo, N., Yamamoto, K., Oda, T., Suzuki, S. and Miura, S. (2007) A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 192, 595-603
18. Hagerkvist, R., Sandler, S., Mokhtari, D. and Welsh, N. (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of β-cell NF-κB activation and anti-apoptotic preconditioning. FASEB J. 21, 618-628
19. Hagerkvist, R., Makeeva, N., Elliman, S. and Welsh, N. (2006) Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol. Int. 30, 1013-1017
20. Atkinson, M. A. and Leiter, E. H. (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 5, 601-604
21. Rakieten, N., Rakieten, M. L. and Nadkarni, M. V. (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother. Rep. 29, 91-98
22. Louvet, C., Szot, G. L., Lang, J., Lee, M. R., Martinier, N., Bollag, G., Zhu, S., Weiss, A. and Bluestone, J. A. (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 105, 18895-18900
23. Han, M. S., Chung, K. W., Cheon, H. G., Rhee, S. D., Yoon, C. H., Lee, M. K., Kim, K. W. and Lee, M. S. (2009) Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/ db mice. Diabetes 58, 329-336
24. Magro, F. and Costa, C. (2006) Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm. Bowel Dis. 12, 1087-1089
25. Paniagua, R. T., Sharpe, O., Ho, P. P., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B. et al. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642
26. Chodorowski, Z., Sein Anand, J., Hellmann, A. and Prejzner, W. (2007) No influence of imatinib on type 2 diabetes. Przegl. Lek. 64, 370-371
27. Dingli, D., Wolf, R. C. and Vella, A. (2007) Imatinib and type 2 diabetes. Endocr. Pract. 13, 126-130
28. Hagerkvist, R., Jansson, L. and Welsh, N. (2008) Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin. Sci. 114, 65-71
29. Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R. and Kufe, D. W. (1995) Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376, 785-788
30. Sun, X., Majumder, P., Shioya, H., Wu, F., Kumar, S., Weichselbaum, R., Kharbanda, S. and Kufe, D. (2000) Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem. 275, 17237-17240
31. Cong, F. and Goff, S. P. (1999) c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc. Natl. Acad. Sci. U.S.A. 96, 13819-13824
32. Goldberg, Z., Vogt Sionov, R., Berger, M., Zwang, Y., Perets, R., Van Etten, R. A., Oren, M., Taya, Y. and Haupt, Y. (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 21, 3715-3727
33. Yoshida, K., Komatsu, K., Wang, H. G. and Kufe, D. (2002) c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol. Cell. Biol. 22, 3292-3300
34. Kawai, H., Nie, L. and Yuan, Z. M. (2002) Inactivation of NF-κB-dependent cell survival: a novel mechanism for the proapoptotic function of c-Abl. Mol. Cell. Biol. 22, 6079-6088
35. Kumar, S., Bharti, A., Mishra, N. C., Raina, D., Kharbanda, S., Saxena, S. and Kufe, D. (2001) Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J. Biol. Chem. 276, 17281-17285
36. Ito, Y., Pandey, P., Mishra, N., Kumar, S., Narula, N., Kharbanda, S., Saxena, S. and Kufe, D. (2001) Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol. Cell. Biol. 21, 6233-6242
37. Oyadomari, S., Takeda, K., Takiguchi, M., Gotoh, T., Matsumoto, M.,Wada, I., Akira, S., Araki, E. and and Mori, M. (2001) Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. Proc. Natl. Acad. Sci. U.S.A. 98, 10845-10850
38. Li, B., Cong, F., Tan, C. P., Wang, S. X. and Goff, S. P. (2002) Aph2, a protein with a zf-DHHC motif, interacts with c-Abl and has pro-apoptotic activity. J. Biol. Chem. 277, 28870-28876
39. Frasca, F., Pandini, G., Malaguarnera, R., Mandarino, A., Messina, R. L., Sciacca, L., Belfiore, A. and Vigneri, R. (2007) Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J. Biol. Chem. 282, 26077-26088
40. Campbell, M., Allen, W. E., Silversides, J. A. and Trimble, E. R. (2003) Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-β receptor potentiates vascular smooth muscle cell chemotaxis. Diabetes 52, 519-526
41. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N. et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946
42. Newton, C. S., Loukinova, E., Mikhailenko, I., Ranganathan, S., Gao, Y., Haudenschild, C. and Strickland, D. K. (2005) Platelet-derived growth factor receptor-β (PDGFR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP): evidence for co-receptor function. J. Biol. Chem. 280, 27872-27878
43. Hansmann, G., Wagner, R. A., Schellong, S., Perez, V. A., Urashima, T., Wang, L., Sheikh, A. Y., Suen, R. S., Stewart, D. J. and Rabinovitch, M. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation. Circulation 115, 1275-1284
44. Hoehn, K. L., Hohnen-Behrens, C., Cederberg, A., Wu, L. E., Turner, N., Yuasa, T., Ebina, Y. and James, D. E. (2008) IRS1-independent defects define major nodes of insulin resistance. Cell Metab. 7, 421-433
45. Lassila, M., Allen, T. J., Cao, Z., Thallas, V., Jandeleit-Dahm, K. A., Candido, R. and Cooper, M. E. (2004) Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 935-942
46. Sadanaga, A., Nakashima, H., Masutani, K., Miyake, K., Shimizu, S., Igawa, T., Sugiyama, N., Niiro, H., Hirakata, H. and Harada, M. (2005) Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum. 52, 3987-3996
47. Reber, L., Da Silva, C. A. and Frossard, N. (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 533, 327-340
48. Sayed, B. A., Christy, A., Quirion, M. R. and Brown, M. A. (2008) The master switch: the role of mast cells in autoimmunity and tolerance. Annu. Rev. Immunol. 26, 705-739
49. Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P. W., Buchdunger, E., Walker, C. and Jarai, G. (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur. J. Pharmacol. 599, 44-53
50. Vogel, W. F., Abdulhussein, R. and Ford, C. E. (2006) Sensing extracellular matrix: an update on discoidin domain receptor function. Cell. Signalling 18, 1108-1116